

La propriété intellectuelle dans l'industrie pharmaceutique

Intellectual Property in the Pharmaceutical Industry

Jean-Christophe Galloux, Peter Beyer, Ahmed Abdel Latif,
Trevor Cook, Hans-Friedrich Czekay, Matthijs Marell/Martin
Senfleben/Manon Rieger-Jansen

Actes de la Journée de Droit de la Propriété Intellectuelle du 10 février 2012



UNIVERSITÉ
DE GENÈVE

FACULTÉ DE DROIT

Schulthess §
ÉDITIONS ROMANDES

Table des matières / *Table of contents*

Avant-propos	V
Sommaire / <i>Contents</i>	IX
Table des abréviations / <i>Table of abbreviations</i>	XV

Le droit des brevets pharmaceutiques en Europe: Quo vadis ?

Jean-Christophe Galloux

I.	La <i>Via Appia</i> : l'acquisition de la protection par brevet dans le domaine pharmaceutique	2
	A. Une voie rectiligne: l'acquisition d'un brevet pharmaceutique	3
	1. La brevetabilité de la seconde application thérapeutique	3
	2. Les revendications de posologie	6
	B. Une voie parfois mal pavée: l'acquisition d'un titre complémentaire au brevet	8
	1. L'acquisition d'un CCP	8
	2. L'octroi d'une extension pédiatrique	10
II.	<i>Ego romam iterum crucifigi</i> : La portée et l'exploitation des titres	13
	A. Le retour vers Rome: la portée d'un titre complémentaire	13
	1. La portée d'un CCP	14
	2. La portée d'une extension pédiatrique	18
	B. Le chemin de croix ? Les limites apportées par le droit de la concurrence	20
	1. Les enseignements tirés de l'enquête sectorielle de la Commission européenne	20
	2. Les nouveaux fronts du droit de la concurrence	22

**Developing Socially Responsible Intellectual Property
Licensing Policies – Non-Exclusive Licensing Initiatives
in the Pharmaceutical Sector**

Peter Beyer

I.	Introduction	27
II.	Current non-exclusive licensing initiatives in the pharmaceutical sector – background	32
III.	Current trends in the development of voluntary licensing programmes in the pharmaceutical industry	36
	A. Products and disease areas	36
	B. The number of licensees	38
	C. Geographical scope of marketing rights – territory	38
	D. Royalties	40
	E. Technology transfer	41
	F. Other aspects	42
IV.	Conclusion/prospective analysis	43
	Annex 1: List of voluntary license agreements and non-assert declarations	47
	Annex 2: Tibotec Pharmaceutical licensed territory for rilpivirine and combination products (112 countries)	57
	Annex 3: Gilead licensed territory for TDF, elvitegravir and cobicistat and Quad (112 countries)	58

**Genetic Resources, Patents and Benefit Sharing: State of Play
and Challenges Facing Multilateral Discussions**

Ahmed Abdel Latif

I.	Introduction	59
II.	The Convention on Biological Diversity and the Nagoya Protocol	60
III.	The WTO TRIPS Council	65
IV.	WIPO	72
V.	Lessons learned: the need for complementary solutions and for going beyond entrenched positions	77
VI.	Managing complexity and ensuring mutual supportiveness between different forums	86
VII.	Conclusion	87

Regulatory Exclusivities for Medicinal Products in the EU

Trevor Cook

I.	Introduction and Overview	89
II.	Regulatory Data Protection (or “Data Exclusivity”)	90
III.	Orphan Medicinal Product Exclusivity	101
IV.	Conclusions	103
Annex 1:	Extracts from Directive 2001/83/EC of 6 November 2001 on the Community code relating to medicinal products for human use, as amended	105
Annex 2:	Extracts from Regulation (EC) 141/2000 of 16 December 1999 on orphan medicinal products and Commission Regulation (EC) 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts “similar medicinal product” and “clinical superiority”	111

Challenges of Pharmaceutical Brand Name Creation

Hans-Friedrich Czekay

I.	Introduction	115
II.	Marketing challenges	116
	A. Brand properties	116
	B. Time lines	117
	C. Process	118
III.	Trademark law challenges	119
	A. Availability of protection	119
	B. Time lines	121
IV.	Regulatory challenges	121
	A. Approval needed	121
	B. Methodology	122
	1. General remarks	122
	2. Requirements to be fulfilled in the European Union	124
	3. Requirements to be fulfilled in the USA	124
	4. Requirements in other countries	126

Trademark Enforcement Issues in the Pharmaceutical Industry

Matthijs Marell / Martin Senfleben / Manon Rieger-Jansen

I.	Introduction to trademark rights.	128
	A. The initial stage of “sign reservation”.	129
	B. The further stage of “brand image creation”	131
	C. Need for Enforcement Measures	132
II.	The tool box for trademark owners in the fight against counterfeit	133
	A. EU Customs Regulation as an important tool for combating counterfeit	134
	B. Transit of counterfeit pharmaceutical products	137
	C. Parallel trade of medicines	139
III.	Conclusion.	141